A FIC monoclonal antibody targeting solid tumors such as gastric cancer and colorectal cancer. BioTroy has been the first to identify the key receptors and functions of this IO target, and the therapeutic potency of the mAb has been validated in multiple models. The MOA of BT01 is shown on the right.
